(Stroke. 1997;28:2338-2346.)
© 1997 American Heart Association, Inc.
Articles |
Lubeluzole Treatment of Acute Ischemic Stroke
From the Department of Neurology, University of Texas Health Science Center at Houston.
Correspondence and reprint requests to James Grotta, MD, Director of Stroke Program, University of Texas Health Science Center, Department of Neurology, 6431 Fannin, Room 7004, Houston, TX 77030. E-mail jgrotta{at}neuro.med.uth.tmc.edu
Background and Purpose Lubeluzole is a novel benzothiazole compound that has shown neuroprotective activity in preclinical models of ischemic stroke. The present multicenter, double-blind, placebo-controlled study was conducted to assess the efficacy and safety of lubeluzole in the treatment of ischemic stroke.
Methods Seven hundred twenty-one patients with clinical symptoms of acute ischemic stroke were randomized to receive either lubeluzole (7.5 mg over 1 hour, followed by a continuous daily infusion of 10 mg for up to 5 days) or placebo. Treatment was initiated within 6 hours of symptom onset. Mortality at 12 weeks was the primary efficacy end point. Secondary efficacy end points included neurological recovery (based on the National Institutes of Health Stroke Scale [NIHSS]), functional status (based on the Barthel Index), and level of disability (based on the Rankin Scale). Safety assessments included standard and continuous electrocardiographic monitoring, physical examination, measurements of vital signs, clinical laboratory evaluation, and adverse events reports.
Results The overall mortality rate at 12 weeks for lubeluzole-treated patients was 20.7% compared to 25.2% for placebo-treated patients (NS). Controlling for relevant covariates, the degree of neurological recovery (NIHSS) at week 12 significantly favored lubeluzole over placebo (P=.033). Lubeluzole treatment similarly resulted in significantly greater improvements in functional status (Barthel Index) (P=.038) and overall disability (Rankin Scale) (P=.034) after 12 weeks. A global test statistic confirmed that lubeluzole-treated patients had a more favorable clinical outcome at 12 weeks (P=.041). The safety profile of lubeluzole resembled that of placebo.
Conclusions Treatment with lubeluzole within 6 hours of the onset of ischemic stroke had a nonsignificant effect on mortality and resulted in improved clinical outcome compared with placebo, with no safety concerns.
Key Words: clinical trials • efficacy • ischemic stroke • lubeluzole • neuroprotection • safety
This article has been cited by other articles:
 |
|
 |
|
  M. D. Ginsberg Current Status of Neuroprotection for Cerebral Ischemia: Synoptic Overview Stroke, March 1, 2009; 40(3_suppl_1): S111 - S114. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Ali, S. Atula, P. M.W. Bath, J. Grotta, W. Hacke, P. Lyden, J. R. Marler, R. L. Sacco, K. R. Lees, and for the VISTA Investigators Stroke Outcome in Clinical Trial Patients Deriving From Different Countries Stroke, January 1, 2009; 40(1): 35 - 40. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Uyttenboogaart, M. W. Koch, R. E. Stewart, P. C. Vroomen, G.-J. Luijckx, and J. De Keyser Moderate hyperglycaemia is associated with favourable outcome in acute lacunar stroke Brain, June 1, 2007; 130(6): 1626 - 1630. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. P. Adams Jr, G. del Zoppo, M. J. Alberts, D. L. Bhatt, L. Brass, A. Furlan, R. L. Grubb, R. T. Higashida, E. C. Jauch, C. Kidwell, et al. Guidelines for the Early Management of Adults With Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Circulation, May 22, 2007; 115(20): e478 - e534. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. P. Adams Jr, G. del Zoppo, M. J. Alberts, D. L. Bhatt, L. Brass, A. Furlan, R. L. Grubb, R. T. Higashida, E. C. Jauch, C. Kidwell, et al. Guidelines for the Early Management of Adults With Ischemic Stroke: A Guideline From the American Heart Association/ American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists Stroke, May 1, 2007; 38(5): 1655 - 1711. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Gongora-Rivera, J. Labreuche, A. Jaramillo, P. G. Steg, J.-J. Hauw, and P. Amarenco Autopsy Prevalence of Coronary Atherosclerosis in Patients With Fatal Stroke Stroke, April 1, 2007; 38(4): 1203 - 1210. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. Dhamoon, R. R. Sciacca, T. Rundek, R. L. Sacco, and M.S.V. Elkind Recurrent stroke and cardiac risks after first ischemic stroke: The Northern Manhattan Study Neurology, March 14, 2006; 66(5): 641 - 646. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Bruno, C. Saha, and L. S. Williams Using Change in the National Institutes of Health Stroke Scale to Measure Treatment Effect in Acute Stroke Trials Stroke, March 1, 2006; 37(3): 920 - 921. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. B. Young, C. J. Weir, K. R. Lees, and for the GAIN International Trial Steering Committe Comparison of the National Institutes of Health Stroke Scale With Disability Outcome Measures in Acute Stroke Trials Stroke, October 1, 2005; 36(10): 2187 - 2192. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Uyttenboogaart, R. E. Stewart, P. C.A.J. Vroomen, J. De Keyser, and G.-J. Luijckx Optimizing Cutoff Scores for the Barthel Index and the Modified Rankin Scale for Defining Outcome in Acute Stroke Trials Stroke, September 1, 2005; 36(9): 1984 - 1987. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. L. Lutsep Current Status of Hemorrhagic Stroke and Acute Nonthrombolytic Ischemic Stroke Treatment Stroke, November 1, 2004; 35(11_suppl_1): 2746 - 2747. [Full Text] [PDF]
|
|
|
|
|
|
C. S. Weaver, J. Leonardi-Bee, F. J. Bath-Hextall, and P. M.W. Bath Sample Size Calculations in Acute Stroke Trials: A Systematic Review of Their Reporting, Characteristics, and Relationship With Outcome Stroke, May 1, 2004; 35(5): 1216 - 1224. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. N. Thijs, D. M. Somford, R. Bammer, W. Robberecht, M. E. Moseley, and G. W. Albers Influence of Arterial Input Function on Hypoperfusion Volumes Measured With Perfusion-Weighted Imaging Stroke, January 1, 2004; 35(1): 94 - 98. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Adams, M. I. Chimowitz, J. S. Alpert, I. A. Awad, M. D. Cerqueria, P. Fayad, and K. A. Taubert Coronary Risk Evaluation in Patients With Transient Ischemic Attack and Ischemic Stroke: A Scientific Statement for Healthcare Professionals From the Stroke Council and the Council on Clinical Cardiology of the American Heart Association/American Stroke Association Circulation, September 9, 2003; 108(10): 1278 - 1290. [Full Text] [PDF]
|
|
|
|
|
|
R. J. Adams, M. I. Chimowitz, J. S. Alpert, I. A. Awad, M. D. Cerqueria, P. Fayad, and K. A. Taubert Coronary Risk Evaluation in Patients With Transient Ischemic Attack and Ischemic Stroke: A Scientific Statement for Healthcare Professionals From the Stroke Council and the Council on Clinical Cardiology of the American Heart Association/American Stroke Association Stroke, September 1, 2003; 34(9): 2310 - 2322. [Full Text] [PDF]
|
|
|
|
|
|
T. Crocco, T. Gullett, S. M. Davis, N. Flores, L. Sauerbeck, E. Jauch, B. Threlkeld, B. Pio, M. Ottaway, A. Pancioli, et al. Feasibility of Neuroprotective Agent Administration by Prehospital Personnel in an Urban Setting Stroke, August 1, 2003; 34(8): 1918 - 1922. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. P. Adams Jr, R. J. Adams, T. Brott, G. J. del Zoppo, A. Furlan, L. B. Goldstein, R. L. Grubb, R. Higashida, C. Kidwell, T. G. Kwiatkowski, et al. Guidelines for the Early Management of Patients With Ischemic Stroke: A Scientific Statement From the Stroke Council of the American Stroke Association Stroke, April 1, 2003; 34(4): 1056 - 1083. [Full Text] [PDF]
|
|
|
|
|
|
S. E. Kasner, A. M. Demchuk, J. Berrouschot, E. Schmutzhard, L. Harms, P. Verro, J. A. Chalela, R. Abbur, H. McGrade, I. Christou, et al. Predictors of Fatal Brain Edema in Massive Hemispheric Ischemic Stroke Stroke, September 1, 2001; 32(9): 2117 - 2123. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Berger, Y. Garnier, T. Lobbert, D. Pfeiffer, and A. Jensen Circulatory Responses to Acute Asphyxia Are Not Affected by the Glutamate Antagonist Lubeluzole in Fetal Sheep Near Term Reproductive Sciences, May 1, 2001; 8(3): 143 - 148. [Abstract] [PDF]
|
|
|
|
 |
|
 R. L. Sacco, J. T. DeRosa, E. C. Haley Jr, B. Levin, P. Ordronneau, S. J. Phillips, T. Rundek, R. G. Snipes, J. L. P. Thompson, and for the GAIN Americas Investigators Glycine Antagonist in Neuroprotection for Patients With Acute Stroke: GAIN Americas: A Randomized Controlled Trial JAMA, April 4, 2001; 285(13): 1719 - 1728. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Uchino, D. Billheimer, and S. C. Cramer Entry Criteria and Baseline Characteristics Predict Outcome in Acute Stroke Trials Stroke, April 1, 2001; 32(4): 909 - 916. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. P. Samsa and D. B. Matchar Have Randomized Controlled Trials of Neuroprotective Drugs Been Underpowered? : An Illustration of Three Statistical Principles Stroke, March 1, 2001; 32(3): 669 - 674. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Caro, K. F. Huybrechts, and H. E. Kelley Predicting Treatment Costs After Acute Ischemic Stroke on the Basis of Patient Characteristics at Presentation and Early Dysfunction Stroke, January 1, 2001; 32(1): 100 - 106. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Fisher and W. Schaebitz An Overview of Acute Stroke Therapy: Past, Present, and Future Arch Intern Med, November 27, 2000; 160(21): 3196 - 3206. [Full Text] [PDF]
|
|
|
|
 |
|
 T. E. Mayer, G. F. Hamann, J. Baranczyk, B. Rosengarten, E. Klotz, M. Wiesmann, U. Missler, G. Schulte-Altedorneburg, and H. J. Brueckmann Dynamic CT Perfusion Imaging of Acute Stroke AJNR Am. J. Neuroradiol., August 1, 2000; 21(8): 1441 - 1449. [Abstract] [Full Text]
|
|
|
|
|
|
P. W. Duncan, H. S. Jorgensen, and D. T. Wade Outcome Measures in Acute Stroke Trials : A Systematic Review and Some Recommendations to Improve Practice Stroke, June 1, 2000; 31(6): 1429 - 1438. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Caro, K. F. Huybrechts, and I. Duchesne Management Patterns and Costs of Acute Ischemic Stroke : An International Study Stroke, March 1, 2000; 31(3): 582 - 590. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Caro and K. F. Huybrechts Stroke Treatment Economic Model (STEM) : Predicting Long-Term Costs From Functional Status Stroke, December 1, 1999; 30(12): 2574 - 2579. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G DEVUYST and J BOGOUSSLAVSKY Recent progress in drug treatment for acute stroke J. Neurol. Neurosurg. Psychiatry, October 1, 1999; 67(4): 420 - 425. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Davis and D. Barer Neuroprotection in acute ischaemic stroke. II: Clinical potential Vascular Medicine, August 1, 1999; 4(3): 149 - 163. [Abstract] [PDF]
|
|
|
|
|
|
G. Sulter, C. Steen, and Jacques De Keyser Use of the Barthel Index and Modified Rankin Scale in Acute Stroke Trials Stroke, August 1, 1999; 30(8): 1538 - 1541. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Berrouschot, H. Barthel, J. Koster, S. Hesse, A. Rossler, W. H. Knapp, and D. Schneider Extracorporeal Rheopheresis in the Treatment of Acute Ischemic Stroke : A Randomized Pilot Study Stroke, April 1, 1999; 30(4): 787 - 792. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. W. Krieger, A. M. Demchuk, S. E. Kasner, M. Jauss, and L. Hantson Early Clinical and Radiological Predictors of Fatal Brain Swelling in Ischemic Stroke Stroke, February 1, 1999; 30(2): 287 - 292. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. W. Muir and D. G. Grosset Neuroprotection for Acute Stroke : Making Clinical Trials Work Stroke, January 1, 1999; 30(1): 180 - 182. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Management soon after a stroke DTB, July 1, 1998; 36(7): 51 - 54. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Fisher and J. Bogousslavsky Further Evolution Toward Effective Therapy for Acute Ischemic Stroke JAMA, April 22, 1998; 279(16): 1298 - 1303. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Lubeluzole for Ischemic Stroke: More Data Needed Journal Watch Emergency Medicine, February 1, 1998; 1998(201): 3 - 3. [Full Text]
|
|